Prior treatment with napabucasin.
Prior treatment with TRC
Prior enrollment in an enfortumab vedotin study or prior treatment with other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).
PRIOR TREATMENT
Patients must have adequate hematologic, liver and renal function =<  days prior to randomization\r\n* NOTE: It is preferred that laboratory values for eligibility be assessed after the last dose of prior treatment, especially in cases where most-recent treatment prior to study entry is chemotherapy
Patients with prior treatment with PLD
Patient has not had prior treatment with blinatumomab
Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted
Previous steroid treatment and/or radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass; emergent steroid treatment and/or radiation treatment should stop once protocol therapy is initiated
Prior treatment with dasatinib, or any BCR-ABL inhibitor other than imatinib
Prior treatment with brentuximab in the last  months or had refractory or progressive disease to prior BV treatment
At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity
Prior treatment with PM, topotecan or anthracyclines.
Prior treatment with alisertib
Prior treatment with PM or trabectedin
Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.
prior treatment failure with at least two cycles of hypomethylating agent.
Prior treatment with idelalisib;
Prior ipilimumab treatment with the exception of adjuvant treatment completed ? months prior to enrollment
Prior treatment with a BCMA-targeted agent
Prior RT or clinically relevant major surgery (e.g. craniotomy, metastasectomy) within  weeks prior to first day of study treatment (for treatment phase)
Prior treatment with venetoclax
Patients must be willing to donate a small amount of whole blood prior to treatment and during treatment for laboratory analysis
Prior treatment (at least  full treatment cycle) with a farnesyltransferase inhibitor.
Any prior treatment with taxotere or carboplatin
Prior treatment with an MDM inhibitor.
No prior treatment with ONC.
Participants with prostate cancer who are unable to interrupt treatment with ketoconazole; ketoconazole treatment must be discontinued  weeks prior to first dose of study medication and is not allowed during Cycle , but may be used in the optional extension phase.
No prior treatment for CAH/EIN/EC
Prior treatment with a RAF inhibitor
Agreement to biopsies before and during treatment, depending on study part
Prior treatment with SGN-LIVA or prior treatment with an MMAE-containing therapy
Prior treatment with WEE inhibitor
Prior treatment with abiraterone or other known potent CYP inhibitors (e.g., ketoconazole, orteronel) or investigational agents that block androgen synthesis. Previous treatment with itraconazole and fluconazole is permitted.
Prior treatment with flutamide (Eulexin), steroidal anti-androgens (e.g., cyproterone acetate, chlormadinone acetate), androgens, or estrogens treatment within  weeks of Cycle , Day 
Prior treatment with Mcl- inhibitor.
Prior treatment (at least  full treatment cycle) with a farnesyltransferase inhibitor.
Prior treatment as follows:
Cytoreduction allowed with hydroxyurea and/or leukapheresis for up to  days prior to day (D) of treatment under LCCC; patients must be off hydroxyurea for >=  hours prior to D of treatment under LCCC
Prior treatment with ERK inhibitors.
Consent for on-treatment paired biopsies
prior treatment with DAC inhibitors
Willingness to have pre treatment and on treatment tumor biopsies.
Prior treatment with PM, trabectedin (Yondelis) or topoisomerase I inhibitors (irinotecan, topotecan, etc.).
Prior treatment with afatinib
Prior treatment with Bromodomain and Extra-Terminal (BET) inhibitor
Treatment with the modified Atkins diet (MAD) for any cause within the  months prior to study enrollment
Patients who have had prior treatment with LY or other Chk inhibitors
Prior treatment with compounds with the same mode of action
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
History of changes in baseline LVEF that occurred during prior treatment with anti-HER treatment
For Cohorts ,  and  only: Has received treatment with rituximab, alemtuzumab, ofatumumab or any other chemotherapeutic agent for CLL. Cohort : Received prior treatment with bendamustine and did not respond during treatment or relapsed less than sex months after completing treatment.
Patients must be either intolerant or refractory to one or more standard line(s) of chemotherapy treatment prior to enrollment; toxicity from prior regimens must be resolved to less than or equal to grade  prior to enrollment; patients with grade  neurotoxicity may be enrolled on a case by case basis at the discretion of the principal investigator; patients should be off all treatment for at least  weeks prior to trial enrollment
treatment with molecular targeted agents within  weeks prior to treatment with APSF.
TREATMENT WITH SJCAR: Detectable disease
Prior treatment with CTLA- inhibitor
Prior history of treatment with blinatumomab
Any prior PSA, MUC, and/or brachyury-targeted immunotherapy (e.g., vaccine) must have been discontinued at least  weeks before initiation of study treatment; subjects must have recovered from all acute toxicities from prior treatment prior to screening for this study
No prior treatment with temozolomide
Previous treatment with carmustine wafer except when administered as first line treatment and at least  months prior to randomization.
Had prior treatment with Gliadel
Prior treatment with an hepatocyte growth factor (HGF)/cMet inhibitor such as rilotumumab, crizotinib, MetMAb, or ARQ
Has an adequate treatment washout period prior to enrollment
Prior treatment with NKTR-.
Extensive concurrent perianal or lower vulvar HSIL or condyloma requiring a different treatment modality than the study treatment, or treatment that cannot be deferred in observation arm, per examining provider
Prior treatment with nintedanib (BIBF)
Any prior treatment for SCCHN
Treatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate]) =<  days prior to treatment
Prior treatment as follows:
Subjects with prior anti-PD-, anti-PD-L treatment. For Arms A and D, subjects may not have had prior -BB treatment. For Arms B and E, subjects may not have had prior OX treatment. For Arms C and F, subjects may not have had prior -BB or OX treatment.
Prior yttrium- radioembolization treatment
Prior treatment with pazopanib
prior treatment as follows:
Prior treatment with irinotecan or temozolomide is permitted
Prior treatment with carotuximab (TRC)
Thrombolytic use (except to maintain IV catheters) within  days prior study treatment
No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigators opinion
Subjects must not have implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery in the investigators opinion
Prior treatment with palbociclib
Prior treatment with venetoclax or other Bcl- inhibitor
FOR ALL PHASES (Ib AND II): Concurrent treatment with postmenopausal hormone replacement therapy; prior treatment must be stopped for at least  days prior to first baseline biopsy
No restrictions on prior treatment to be eligible
Subjects must have received intravesical treatment with at least two doses of BCG within six months of nivolumab treatment initiation
No prior treatment with ONC
Prior treatment with axitinib
Prolonged antibiotic treatment (>=  days, within  weeks of enrollment) as prevention or suppression of an ongoing infection, where treatment involves gut-perturbing anti anaerobic antibiotics
Treated with or eligible to commence prophylactic treatment with a proton-pump inhibitor prior to implantation, and to continue to receive treatment for at least  months post implantation
Prior treatment with trabectedin
Not suitable for SBRT treatment
Patient who has had prior treatment with mistletoe
Prior treatment with either venetoclax or ibrutinib
Prior treatment with all-trans retinoic acid (ATRA) or systemic retinoid for the treatment of hematologic malignancy.
Patients may concurrently receive bisphosphonates or rank ligand inhibitors while on this study if necessary for treatment or prevention of osteopenia or osteoporosis; prior treatment with LHRH agonists is allowed for premenopausal women; topical vaginal estrogen therapy is allowable
Prior treatment with DCC-
Prior treatment with idelalisib
No prior treatment with carmustine wafers
Prior treatment with lenvatinib
Active treatment for VTE
History of treatment with ibrutinib or blinatumomab
Has history of not tolerating interferon treatment
Dose expansion - KRAS mutant patients groups: Prior treatment with a RAFi (including any BRAFi and pan-RAFi), MEKi and/or ERKi. BRAF mutant patients group: Prior treatment with an ERKi and/or a pan-RAFi.
Anticipated ribonuclease inhibitor (RAI) treatment within  weeks of treatment
Prior treatment with temozolomide, dacarbazine or procarbazine
Patients having received prior radiotherapy, treatment with cytotoxic agents, treatment with biologic agents or any anti-cancer therapy for a non-AML malignancy within the  weeks prior to treatment with selinexor, or those who have not fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with cytotoxic drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as noted before most recent treatment)
Prior treatment with intracystic P- or intracystic bleomycin
Have received treatment with any form of therapy with CYP inhibitory activity such as ketoconazole, aminoglutethimide, or an antiandrogen such as bicalutamide within  months of study treatment initiation
Prior treatment with venetoclax or ibrutinib
Received prior treatment or receiving current treatment for this malignancy
Any prior treatment with: ipilimumab
Patients will be required to have received prior treatment with azithromycin for at least  months prior to enrollment, unless there is evidence of progression or unsatisfactory response while on azithromycin prior to  months of treatment, as deemed by the treating or referring physician; patients who are on azithromycin will need to discontinue for at least  weeks prior to enrollment
In first or subsequent relapse, or refractory to the last treatment (defined as less than a complete metabolic response to the last treatment, or within  months from the last treatment).
Disease staging approximately within one month of treatment
Prior treatment for endometrial cancer
CAPMATINIB INCLUSION CRITERIA: Prior treatment with at least one Food and Drug Administration (FDA)-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
CERITINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
REGORAFENIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
ENTRECTINIB INCLUSION CRITERIA: Prior treatment with at least one FDA-approved drug for unresectable/metastatic melanoma; patients who are treatment-naive but who refuse available standard options and prefer to enroll on this study as their first line of treatment after a thorough informed consent process will be eligible at the discretion of the treating physician
Prior treatment with anthracyclines
Subjects with prior treatment with an MDM inhibitor
No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigators opinion
Either: \r\n* Relapsed after or refractory to prior treatment with at least two regimens or lines of treatment\r\n* Prior failure of at least one regimen or line of treatment, with poor cytogenetic or other risk factors, and ineligible for other clinical trials
Prior treatment with an Murine Double Minute  (MDM) antagonist
No more than  prior progressions
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Prior treatment with crizotinib, or any other cMET or HGF inhibitor
Patients receiving treatment with medications that cannot be discontinued at least  week prior to first INC treatment and for the duration of the study:
Prior treatment with immune-modulating agents within  days before REGN
Have current second malignancy at other sites, which requires treatment, or in the judgement of the Investigator, may require treatment within the next year. Concurrent malignancies that do not require treatment and are clinically stable are allowed. A past history of other malignancies is allowed as long as the subject is not receiving specific treatment other than hormonal therapy, and, in the judgement of the Investigator, is unlikely to have a recurrence.
Prior surgical treatment of the area (i.e., revision cases); a biopsy does not constitute prior surgical treatment
Prior treatment with CCR and/or CCR inhibitors
Prior treatment with leflunomide
Prior treatment with TRC
Trastuzumab treatment within the last  months
Received ?  typical regime for the treatment of ITP. Splenectomy is considered one standard ITP treatment
Treatment with IVIG ?  days prior to the first dose of PRTX-
Treatment with an anti-Rh D antigen agent (e.g. WinPho) ?  days prior to the first dose of PRTX-
Prior treatment with crenolanib with progression on treatment
Prior treatment with talazoparib
Prior treatment with copanlisib
Prior chemotherapy treatment for AML within  days from the initiation of HCT conditioning; Note, use of hydroxyurea or other low intensity treatment not intended to induce remission are acceptable
Prior treatment with an MDM inhibitor.
Prior treatment with topotecan.
Prior treatment with cytotoxic and biological agents is permissible; there should be at least a -week break between prior treatment and the protocol treatment
The surgical treatment must be intended to be a lumpectomy
Have body temperature >F (.C) immediately prior to study treatment.
Treatment with androgens within  months prior to study enrollment
Local-regional treatment sites must be able to be encompassed within a reasonable radiation therapy treatment volume
Patient who has had prior treatment with demethylating agents
Prior use of venlafaxine specifically for treatment of pain (prior use for treatment of other indications, such as hot flashes, is permitted)
Patient receiving treatment likely to cause hemolysis or under phenytoin treatment.
Only patients that have not received any prior treatment for pancreas cancer are eligible for this treatment protocol
Prior treatment with capecitabine or lapatinib
Prior treatment with omacetaxine
Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted
Prior treatment with eribulin
Initiation of immunotherapy (such as trastuzumab-Herceptin) in the  days before treatment; patients who have been on trastuzumab for at least  days prior to treatment with progressive or stable disease are permitted to enroll, but required to stay on trastuzumab for the duration of the study
Patients must not have had prior treatment with floxuridine (FUDR)
Prior history of treatment with ponatinib
Prior treatment with murine F is allowed; patients with prior mF, chimeric (ch). or hu. treatment must have human anti-huF antibody (HAHA) antibody titer less than the upper limit of normal (defined as mean + *standard deviation [SD] of normal volunteers)
Prior treatment with an FTase inhibitor
TREATMENT:
Pre-treatment tests must be performed within  days prior to enrollment
Active pneumonia within  month prior to starting treatment
No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigators opinion
No hormone ablation for two months prior to enrollment, or during treatment
Prior treatment with idelalisib
Prior treatment with ASN or another ERK/ inhibitor
Prior treatment for rectal cancer.
Prior treatment with crizotinib or any other cMET or HGF inhibitor
Prior Temozolomide treatment
Change in the symptomatic treatment of mastocytosis or administration of any new treatment of mastocytosis within  weeks prior to baseline
At study entry, participants must be actively receiving treatment with single-agent PCI- or participants must have participated in a PCI- randomized clinical study in which they initially received comparator treatment and now cross-over to ibrutinib. Note: A minimum of  months requirement for prior PCI- treatment will not be mandatory in this case and participants with less than  months will be required to have more frequent initial safety assessments
Had prior treatment with napabucasin.
Prior treatment with an investigational EZH inhibitor
No prior treatment with wee kinase inhibition
Additional Exclusion Criteria for subjects Assigned to Treatment A: Subjects unable to tolerate antithrombotic prophylaxis must be excluded; Discontinuation of prior treatment with lenalidomide due to intolerable AEs.
Prior treatment with sipuleucel-t and Ra- is permitted, provided there has been a two-week washout from the last dose
Using any systemic treatment for BCC (e.g. vismodegib), or any topical treatment for their BCC tumors, unless discontinued at least one month prior
Patients with prior treatment with idelalisib.
Prior treatment with trabectedin or trabectedin analog
Has had prior treatment with idelalisib
Trastuzumab treatment within the last  months
Prior treatment with guadecitabine.
Subjects with prior treatment with an MDM inhibitor
Patients with prior treatment with hypomethylating agents
Prior treatment with fluoropyrimidines (applicable to Part  only)
Has prior treatment with Gliadel unless it was administered as first line treatment and at least  months prior to study treatment
Prior treatment, involving interferon, anakinra, imatinib, steroids, chemotherapy with, but not limited to cladribine, vinblastine, -mercaptopurine and etoposide, or other medications used empirically for the treatment of ECD, will be acceptable; these therapies should have been completed and discontinued  weeks or more prior to enrollment in this study
Prior treatment with TPI 
No implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and treatment delivery
Time from last anti-tumor treatment to first radiation treatment at least  week
Prior treatment with radium-
Prior treatment with Erwinaze
Prior treatment with dasatinib, imatinib or nilotinib
Prior treatment with trastuzumab
AT TIME OF TREATMENT:
AT TIME OF TREATMENT:
No prior treatment with LMB-
Prior treatment with IMGN
Use of T cell depleting agents for prevention or treatment of rejection at any point prior to or after enrollment in the study
Prior treatment with quizartinib or participated in a prior quizartinib study.
Prior treatment with imetelstat
Prior treatment with eribulin
History of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day  until resolution of the UTI (even if this extends the screening period requirements to start of Vicinium treatment).
Prior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last  years
Has had a prior radium treatment or treatment with other therapeutic radiopharmaceuticals for prostate cancer
Any prior treatment with axitinib.
Patients with prior trastuzumab treatment
Planned treatment with biological agents within  days prior to receiving TheraSphere (may resume after Y- treatment or immediately if in control arm)
Prior treatment with an immune-therapy.
Prior treatment with TRC
Prior treatment with prolifeprospan  with carmustine wafer.
Willingness to provide pretreatment and on-treatment biopsies.
For treatment-nave subjects only:
Prior treatment with entrectinib.
Immediate prior therapy with a PAM pathway inhibitor (i.e., the subject is excluded if the last treatment regimen, prior to MSCA, was a PAM pathway inhibitor, or if the last PAM pathway inhibitor that the subject was treated with occured less than  months prior to Day  of trial drug treatment).
Prior treatment with PM or trabectedin.
Adults with ALL in need of treatment
Prior treatment with nintedanib
Previously untreated and not receiving any other agent that would be considered as a treatment for the lymphoma; for subjects with severe systemic symptoms, compressive disease, or rapidly progressing symptomatic adenopathy, are allowed for lymphoma associated symptom treatment with up to  mg/kg/day prednisone, or equivalent, for a maximum of  days is permitted prior to beginning the treatment, at the discretion of the investigator; a washout period does not apply
No prior treatment except patients may be entered if they have had prior limited-field radiotherapy, a short course of glucocorticoids, cyclophosphamide for an urgent problem at diagnosis (e.g. epidural cord compression, superior vena cava syndrome) and/or a single dose of intrathecal methotrexate (MTX) at the time of the pre-treatment diagnostic lumbar puncture
No prior treatment with cetuximab
Documented meningococcal vaccination not more than  years prior to, or at the time of, initiating study treatment.
No prior systemic treatment for ES-SCLC
Subject must be deriving benefit from continued treatment without any persistent intolerable toxicity from continued treatment of ASP.
Prior treatment with fulvestrant
Prior irinotecan treatment
Prior treatment with rigosertib;
Prior yttrium- microsphere treatment to the liver
Prior treatment with plitidepsin.
Documented meningococcal vaccination not more than  years prior to, or at the time of, initiating study treatment.
Treatment with a complement inhibitor at any time.
Prior treatment with lenvatinib.
Live vaccines should ideally not be administered to any patients undergoing treatment with chemotherapy or immunotherapy, but if need be, they should be administered > months prior to the initiation of treatment or > months after the completion of all treatment
Has prior treatment with Gliadel (carmustine) unless it was administered as first line treatment and at least  months prior to study treatment
On treatment with eculizumab (Soliris) for at least  months
Prior treatment with temozolomide, dacarbazine or procarbazine
Prior treatment with bleomycin
Treatment-nave
TREATMENT
TREATMENT
Disease staging approximately within one month of treatment
Prior treatment with irinotecan, topotecan, or dinutuximab.
Preemptive treatment with retinoic acid prior to exclusion of APL ?  days
Prior treatment with IMGN
Prior treatment with neratinib
Prior treatment with imetelstat
Treatment with short-acting somatostatin analogs less than  days and Sandostatin depot injection less than  weeks before scanning and treatment
Prior treatment with fulvestrant
No prior treatment with carmustine wafers
History of topotecan treatment for SCLC
New systemic immune suppressive agent added for the treatment of chronic GVHD within  weeks prior to enrollment\r\n* Addition of a new systemic immune suppressive treatment simultaneously with ixazomib is also prohibited
Prior treatment with doxorubicin, epirubicin, idarubicin, and/or other anthracyclines or anthracenediones; the participant has received treatment with olaratumab or has participated in a prior olaratumab trial.
Actively breastfeeding women unless it is interrupted during treatment and at least  weeks after treatment discontinuation
Prior treatment with dasatinib
Prior treatment with PM, trabectedin, or with both PLD and topotecan.
ELIGIBILITY FOR TREATMENT ON ARM : Ninety days must have passed since the last definitive doses of radiation or chemoradiation treatment prior to T cell infusion (to avoid confounding pneumonitis)
Patients willing to have regular blood draws, one before treatment and four during or after treatment
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
Prior treatment with ibrutinib
Current treatment or known prior treatment with ribavirin
Prior treatment with cetuximab or panitumumab
Prior treatment with an HGF/cMet inhibitor such as rilotumumab, crizotinib, MetMAb (onartuzumab), or ARQ (tivantinib)
Prior treatment with bosutinib.
Prior treatment with ponatinib.
Prior treatment with pertuzumab, Lapatinib, and/or Trastuzumab emtansine is allowed; however, the last treatment for MBC must not include Trastuzumab in combination with pertuzumab.
Prior treatment with Trastuzumab in combination with Lapatinib or prior treatment with an irreversible inhibitor of the intracellular domain of the HER receptor such as neratinib
Prior treatment with MMB
Prior treatment with bortezomib
Prior treatment with BBI.
Prior treatment with radium- dichloride
Prior treatment with a topoisomerase I inhibitor (i.e. irinotecan, topotecan)
History of prior venetoclax treatment
Prior treatment according to protocol-defined criteria
Preemptive treatment with retinoic acid prior to exclusion of APL ?  days;
Additional experimental anti-cancer treatment and/or standard chemo-, immunotherapy, hormone treatment (with the exception of megestrol acetate), or concurrent radiotherapy is not allowed concomitantly with the administration of study treatment; Zr-trastuzumab use as imaging agent for Zr-trastuzumab PET permitted
Concomitant anti-neoplastic treatment is not allowed during protocol treatment and should be completed at least  weeks prior to commencement of protocol treatment, with resolution of associated acute toxicities. Bisphosphonates are permitted without restriction even during protocol treatment.
Prior treatment with second generation anti-androgens
Prior treatment with a topoisomerase-I inhibitor (e.g., topotecan, irinotecan)
The most recent treatment prior to enrollment must be one of the following (duration of treatment >=  weeks), and must have been adequately tolerated according to the treating physician's judgment\r\n* Letrozole\r\n* Exemestane\r\n* Exemestane + everolimus (everolimus must be discontinued for >=  weeks prior to starting study treatment)\r\n* Letrozole or exemestane in combination with an experimental agent(s) on a clinical trial, provided that the experimental agent(s) is not a PIK inhibitor or v-akt murine thymoma viral oncogene homolog  (AKT) inhibitor (experiment agent[s] must be discontinued for >=  weeks prior to starting study treatment)
Treatment nave patients
Prior treatment with eribulin
Subjects may be receiving anti-cancer treatment, but this treatment should be have been instituted at least  weeks prior to enrollment, and may not change during the study period
Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment.
Prior treatment with trastuzumab emtansine
Prior treatment with CGM or other p/HDM-interaction inhibitor
Prior treatment with KW- or vorinostat.
Any treatment in a BMS- (Nivolumab) trial
Prior treatment with an anti-angiogenic agent is not an exclusion criterion.
Prior treatment with Alpharadin (Xofigo)
Within  weeks of treatment initiation (day ), have received at or adjacent to the target treatment lesions:\r\n* Any surgical procedures other than biopsies related to CTCL diagnosis or follow up\r\n* Any topical treatment other than bland moisturizers (creams, lotions, emollients, etc)
Prior crenolanib treatment for a non-leukemic indication
Prior treatment with eribulin
Complete initial work-up within  days prior to treatment that allows definite staging
Prior bevacizumab as st line treatment for GB (if treatment was concluded  months prior to enrollment, the patient may be eligible to participate in the trial)
Prior therapies for treatment of HL including involved field radiation therapy or any prior treatment for any malignancy with anthracyclines
Prior treatment with fulvestrant
Currently benefitting from continued treatment and have an acceptable safety profile with GSK as determined by the investigator following previous treatment with GSK either as monotherapy or as part of a combination treatment regimen.
Complete initial work-up within  days prior to treatment that allows definite staging.
Either no previous trans-hepatic arterial treatment or progressive hepatic metastasis after prior regional treatment with trans-arterial embolization; embolization of hepatic artery with different types of medication will be considered to be one regional treatment
For patients with MPN: Ruxolitinib treatment requirements will be waived for patients who have failed this treatment in the past or for whom this treatment is otherwise contraindicated
Prior treatment with treatment doses of capecitabine (prior radio-sensitizing doses of capecitabine are allowed as long as the patient did not progress on capecitabine)
Patients must have an indication for treatment by  IWCLL Criteria
Patients receiving treatment with -alpha reductase inhibitors (e.g., finasteride, dutasteride) within  days prior to preregistration are not eligible; treatment with these agents during the protocol intervention is not permitted
Prior treatment with MDV
Prior treatment with ketoconazole
Prior treatment with HAI FUDR
Indication A - ASPS: Subjects with no prior therapy or subjects with prior treatment with chemotherapy or an angiogenesis inhibitor (e.g., sunitinib).
a. Indication A - ASPS: Prior treatment with cediranib.
Less than  days since last treatment used to treat the disease
Prior history of treatment with dasatinib
Prior treatment with temozolomide, dacarbazine or procarbazine.
Prior irinotecan treatment.
Osteoporosis requiring treatment at the time of randomization or treatment considered likely to become necessary within the subsequent six months
Prior treatment with cabazitaxel
Prior treatment with ibrutinib
Treatment with immune modulators including
Prior treatment with pacritinib
Prior treatment with BIBF  or any other VEGFR inhibitor within  weeks
Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
Subjects must be able to receive outpatient treatment and laboratory monitoring (where specifically indicated) at the institution that administers study drug for the entire treatment period
Prior treatment with afatinib or any other HER inhibitor other than trastuzumab
Prior treatment with bortezomib
Prior treatment with TPI 
TREATMENT:
ENROLLMENT INTO THE TREATMENT ARMS:
Prior treatment with AN-
Participants may be treatment naive, refractory to or intolerant of one or more prior therapies, or treated with prior systemic treatment including but not limited to liposomal doxorubicin
Have received at least one prior course of treatment for ccRCC. Part C only: Prior treatment must include at least  course of VEGF-directed therapy.
Serum cholesterol < ULN with or without treatment for hyperlipidemia; if > ULN and untreated, may be rescreened for eligibility after treatment
Prior treatment with MMB
Prior treatment with TNFRSF agonists.
Prior treatment with more than  lines of cytostatic therapies for metastatic disease unless specifically agreed between investigator and sponsor. Subjects with a history of any prior Grade =/>  toxicity associated with taxane treatment will be excluded.
Requires initiation of daily PE treatment and has received  PE treatment prior to randomization
Prior sunitinib treatment.
Prior treatment with mirvetuximab soravtansine
Prior treatment with ANG/GRN
Patients must not have received prior anticancer treatment for metastatic disease (for example, but not limited to, systemic, local, radiation, radiopharmaceutical). -Exceptions: Surgery for melanoma and/or postresection brain radiotherapy (RT) if central nervous system (CNS) metastases and/or prior treatment with adjuvant interferon (IFN) (as described in Exclusion Criterion ).
Eligible and agreeable for percutaneous biopsy of a primary or metastatic lesion prior to treatment and after approximately  weeks of treatment
Prior treatment with trastuzumab, pertuzumab, and T-DM, either alone or in combination, is required.
Prior treatment with selinexor
Prior crenolanib treatment for a non-leukemic indication
Has received prior treatment with ONT- or varlilumab, or prior treatment with other MUC vaccines or CD-targeted agents
Any prior treatment with topoisomerase I therapy.
Prior treatment with BBI.
Able to initiate study treatment within  weeks of completion of last chemoradiation treatment;
Prior treatment with a compound of the same mechanism
Prior treatment with filanesib (ARRY-) or any other KSP inhibitor.
Antimicrobial treatment active against CDAD administered for >  hours except for metronidazole treatment failures (MTF)
Prior vemurafenib treatment
Hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes
History of treatment with an asparaginase agent
Prior treatment with IL within the last  years
Prior treatment with cabazitaxel
Prior history of treatment with ABT-
Patients receiving treatment with bupropion.
Prior treatment with AEZS-.
Patients with a history of prior treatment with ipilimumab
Prior treatment with TRC
Patients with a history of prior treatment with ipilimumab or dasatinib
Prior treatment with floxuridine (FUDR)
Prior treatment with HAI floxuridine (FUDR)
Prior treatment with AIs
Patients who are receiving treatment with statins that are known to cause rhabdomyolysis and that cannot be discontinued at least  days prior to starting LDE treatment
Prior treatment with PM.
Prior treatment with pazopanib.
Part A: Unable to swallow tablets. Intolerant of therapy with erlotinib. Concomitant treatment with the cytochrome P A (CYPA) modulators. Must not have received treatment with any of these modulators within  days of study treatment.
prior treatment with PF-
Prior treatment with taxanes or anthracyclines is required;
Prior treatment with obinutuzumab
Prior treatment with tamoxifen, raloxifen or aromatase inhibitors for reduction in risk (chemoprevention) of breast cancer and/or treatment for osteoporosis within last  years
Patients who have been on a statin other than simvastatin within  weeks of starting treatment on current study; these include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, and rosuvastatin; if patient is on statin, will need to stop treatment  weeks prior to starting treatment on study
Prior treatment with selective inhibitor of nuclear export (SINE) inhibitor
Patients receiving non-intensive treatment
Documented investigator-assessed relapse or progression after the last treatment is required if the participant responded and then progressed on the prior treatment.
Prior treatment with selinexor
Prior treatment with the Optune system.
Planned treatment with any VEGF?TKI treatment with treatment has not yet begun
Provides consent for his/her own treatment and procedures
Anytime from treatment
Off-treatment and progression-free for at least  months and =<  years; treatment cessation is defined as the final dose of chemotherapy, the last dose (fraction) of radiation, or date of surgery, whichever occurred last
Prior treatment with Scrambler therapy
Received treatment for breast cancer, and treatment must have been completed at least  weeks prior to enrollment in trial, but no longer than  years post-treatment
Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor.
Treatment for hyperleukocytosis with hydroxyurea;
Prior treatment with either obinutuzumab or ibrutinib
Prior treatment with an inhibitor that is targeted primarily to FGFRs
Prior use of probiotics within  months prior to enrollment
AYA has initial or relapsed cancer diagnosis and is actively on treatment and will continue to be on treatment long enough to complete the intervention and evaluation ( to  weeks)
Subjects who have had a venous or arterial embolic event AND who have received anti-coagulant treatment, where both the event and the treatment were within six months of the first Investigational Product administration
Sexually active prior to cancer treatment (>=  on the Sexual Health Inventory For Men?[SHIM])
Men randomized to the treatment arm should not father a baby while receiving topical treatment during this study; men who could father a child must agree to use at least one form of birth control during or continued abstinence from heterosexual intercourse if receiving topical treatment during the study, and for  weeks after stopping topical treatment
Treatment or removal of HSIL less than  months prior to randomization
History of autoimmunity that has not been controlled with treatment in the last  months
No prior history of NMSC in the treatment fields
No actinic keratosis (AK)/Bowens disease in the treatment fields within the last  months
Patients on treatment with tamoxifen
Prior or concurrent eczema or other eczemoid skin disorders or active skin condition (acute, chronic, or exfoliative) that disrupts the epidermis; persons with psoriasis are not excluded except in cases of:\r\n* any active lesion\r\n* any active lesion in the previous  months that required treatment, either systemic or topical\r\n* any prior episode, at any time, extensive enough or severe enough as to require systemic treatment
Treatment with other oral hypoglycemic agents
TREATMENT GROUP
TREATMENT GROUP
Subjects who received prior treatment or are already receiving everolimus treatment prior to study entry are not eligible.
Patients may have had treatment for no more than  prior relapses
Prior treatment with capecitabine
Treatment with brivudine, sorivudine, or its chemically-related analogs ?  days prior to the date of Randomization
There will be no restrictions on prior treatment
Prior endoscopic treatment for BE
Treatment plan for HDC-ASCT
Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or cytarabine more than  g per square meter
Allowable type and amount of prior therapy: patients with newly diagnosed malignancies should not have initiated treatment for their disease before participating in this study; patients with recurrent or second malignancies may have had prior therapy as appropriate for their disease, but should have completed all prior treatment at least  days before participation in this study and should not have initiated new treatment for the current problem
Participants undergoing active treatment, or who have completed treatment, will have radiographic abnormalities that may or may not be recurrent tumor
Prior treatment
Prior treatment with a topoisomerase I inhibitor
Prior treatment with cetuximab with tumor progression during or within  months after completing treatment.
Treatment-nave/Unfit Cohorts Only: Any prior anti-leukemic therapy (excluding hydroxyurea or oral etoposide), prior treatment with hypomethylating agents and/or low dose cytarabine.
Prior treatment with SL-
Prior treatment with venetoclax or other BCL inhibitors
Actively breastfeeding women unless it is interrupted during treatment and at least  weeks after treatment discontinuation
Prior treatment with sipuleucel-T
No treatment with systemic anti-cancer treatment (chemotherapy or biologics) within  weeks of starting interferon gamma
Prior treatment with MORAb-
Prior treatment with SS(dsFv)PE (SSP)
Prior treatment with trabectedin
Patients must be registered to the study within  working days after being seen by surgical team for MBO or within  working days after completion of indicated treatment (e.g. total parenteral nutrition [TPN], anticoagulation reversal) to make them eligible for surgical intervention, whichever is later, and prior to any treatment (surgical or non-surgical) for MBO; treatment is defined as any medication or invasive interventions beyond nasogastric decompression, hydration, pain medications or antiemetic medications; NOTE: somatostatin analogues may be used prior to registration if that use is limited to not more than the two days just prior to registration
Prior treatment with PM.
Prior treatment with BLZ-.
Patients who are not candidates for RT treatment
Patients must be without seizures for at least  days prior to enrollment, and patients who receive treatment with AEDs must be on stable doses for at least  days prior to enrollment
Prior treatment with TGR-
Prior treatment with lenvatinib.
Prior treatment with TRC
No prior treatment by cetuximab except if given for primary treatment (locally advanced disease) with no progressive disease for at least  months following the end of prior cetuximab treatment.